Document Detail


Aliskiren: beyond blood pressure reduction.
MedLine Citation:
PMID:  20812878     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: Hypertension is one of the most important risk factors and causes of cardiovascular disease (CVD). From some years, renin-angiotensin-aldosterone system (RAAS) inhibitors such angiotensin converting enzyme (ACE) and angiotensin receptor blockade (ARB) have been of interest, not only for better blood pressure (BP) control but also for their involvement in the mechanisms of various organ functions.
AREAS COVERED IN THIS REVIEW: The aim of this review is to focus on the effectiveness and safety of aliskiren beyond the treatment of hypertension.
WHAT THE READER WILL GAIN: Aliskiren, the first approved renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic non-peptide molecule that blocks angiotensin I generation. Because of its mechanism of action, aliskiren may offer the additional opportunity to inhibit progression of atherosclerosis at tissue level and the potential to be useful in a wide spectrum of conditions. However, we will discuss how it might become a reasonable therapeutic choice also in a broad number of clinical conditions, sharing an increased cardiovascular risk as stable coronary artery disease (CAD), microvascular and cardio-renal disease, diabetes, and peripheral arterial disease (PAD).
TAKE HOME MESSAGE: Therapy of hypertension through a better blockade of RAAS may be the first step in also achieving interesting results in the complications that hypertension causes in several organs.
Authors:
Graziano Riccioni; Nicola Vitulano; Alessandra Zanasi; Fulvio Bellocci; Nicolantonio d'Orazio
Related Documents :
25196678 - Tight blood glycaemic and blood pressure control in experimental diabetic nephropathy r...
884878 - Prevention by somatostatin of rise in blood pressure and plasma renin mediated by beta-...
600948 - Treatment of severe hypertension in chronic renal failure by haemofiltration.
6344658 - Factors that alter the plasma renin activity of the marmot.
24485698 - Preventing the collapse of a peripheral vein during cannulation: an evaluation of vari...
10720858 - Detrusor contraction duration may predict response to alpha-blocker therapy for lower u...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  19     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1265-74     Citation Subset:  IM    
Affiliation:
Cardiology Unit, San Camillo Hospital, via Isonzo, 71043 Manfredonia, Foggia, Italy. griccioni@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investig...
Next Document:  Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics.